<DOC>
	<DOCNO>NCT00608868</DOCNO>
	<brief_summary>The purpose study evaluate ORR ( Objective Response Rate ) gefitinib second-line therapy NSCLC patient base RECIST ( Response Evaluation Criteria Solid Tumors Group ) check ORR difference EGFR mutation , gender , smoke history , type tumor .</brief_summary>
	<brief_title>SELINE : Second-Line Iressa Phase IV Study NSCLC Patients</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Pathological Diagnosis local advanced/metastatic Non Small Cell Lung Carcinoma Previously fail firstline chemotherapy Patient provide sample EGFR mutation test Central Nervous System metastasis spinal cord compression yet definitively treat surgery and/or radiation Any evidence clinically active interstitial lung disease</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Carcinoma</keyword>
	<keyword>Non Small Cell Lung</keyword>
	<keyword>EGFR mutation</keyword>
	<keyword>Gefitinib</keyword>
</DOC>